AUG 19, 2019 9:36 AM PDT

FDA Approves New Treatment for Extensively Drug-Resistant TB

WRITTEN BY: Tiffany Dazet

Last week, the U.S. Food and Drug Administration (FDA) approved a new treatment for a severe form of multi-drug-resistant tuberculosis of the lungs. According to a press release from the FDA, the treatment consists of a six-month regimen of pretomanid tablets combined with bedaquiline and linezolid—referred to as the BPaL regimen. This is one of three tuberculosis treatments to gain FDA approval in the past 40 years. During clinical trials, about 90% of participants using this treatment recovered within six months.

It’s estimated that 1.6 million people die from tuberculosis every year, killing more than any other infectious disease. An article in Nature states that half a million people worldwide are diagnosed with multi-drug-resistant tuberculosis every year. Of those, 8.5% have XDR TB—extensively drug-resistant tuberculosis—which according to RTI, is resistant to four of the main tuberculosis treatments currently in use worldwide. Mel Spigelman, president of the TB Alliance, told Nature “drug-resistant TB is the largest single source of antimicrobial resistance in the world.”

Pretomanid was developed by RTI International as part of the TB Alliance, which is a non-profit product development partnership established in 2000. The team was led by Dr. Doris Rouse, as RTI International scientist. In a statement from RTI, Dr. Rouse said “I’ve been in wards with patients that are so emaciated, they won’t eat anything, they have fevers, they can’t sleep. But with pretomanid, in a regimen that contains two other drugs, bedaquiline and linezolid, we see improvement within a few weeks.”

The development of pretomanid took nearly 20 years. Dr. Rouse commented, “We’ve worked on this new drug for 19 years and it hasn’t always been an easy path. But as I’ve always said, ‘One of the main ingredients for successful drug development is blessed stubbornness.’”

Affordable pricing will be a major hurdle to make the treatment accessible to impoverished patients. According to Sharonann Lynch, the TB advisor for Doctors Without Borders, only 20% of those who needed bedaquiline were able to afford it. Nature states that a six-month supply of bedaquiline and delaminid can cost hundreds to thousands of dollars. The price of the new treatment is currently under negotiations by the TB Alliance.

Sources: FDA, RTI, Nature
 

About the Author
  • Tiffany grew up in Southern California, where she attended San Diego State University. She graduated with a degree in Biology with a marine emphasis, thanks to her love of the ocean and wildlife. With 13 years of science writing under her belt, she now works as a freelance writer in the Pacific Northwest.
You May Also Like
OCT 01, 2021
Microbiology
Understanding How the Gut Microbiome is Affected by Temperature
OCT 01, 2021
Understanding How the Gut Microbiome is Affected by Temperature
The gut microbiome has become an area of intense research focus in recent years. Genomic tools have enabled scientists t ...
OCT 05, 2021
Microbiology
Insects & Spiders Seem to Carry & Spread Antibiotic Resistance
OCT 05, 2021
Insects & Spiders Seem to Carry & Spread Antibiotic Resistance
Antibiotic resistance is seen as a growing threat to public health, and scientists have been trying to develop new antib ...
OCT 13, 2021
Chemistry & Physics
The Nobel Prize in Chemistry
OCT 13, 2021
The Nobel Prize in Chemistry
It's Nobel Prize season, and the third to be awarded was in the field of Chemistry. The winners were two men working on ...
OCT 19, 2021
Drug Discovery & Development
Researchers develop a potent antiviral drug for dengue fever
OCT 19, 2021
Researchers develop a potent antiviral drug for dengue fever
Dengue fever is a mosquito borne illness that is widespread, especially in tropical countries. The global incidence of d ...
OCT 21, 2021
Neuroscience
Phone-based Talk Therapy Eases Arthritis-related Insomnia
OCT 21, 2021
Phone-based Talk Therapy Eases Arthritis-related Insomnia
Talk therapy practice known as cognitive behavior therapy (CBT) conducted over the phone helps older adults with arthrit ...
OCT 21, 2021
Cannabis Sciences
Cannabis as a Prospective Treatment for Fibromyalgia? - Emerging Evidence
OCT 21, 2021
Cannabis as a Prospective Treatment for Fibromyalgia? - Emerging Evidence
Fibromyalgia is a common disease impacting millions of adults in the United States. The condition can be extremely debil ...
Loading Comments...